(PharmaNewsWire.Com, April 16, 2018 ) Commonly termed as the flu, influenza is an infectious disease caused by the influenza virus. The symptoms of the disease range from being severe to very mild in nature. Runny nose, muscle pains, feeling tires, coughing, and high fever are some of the common symptoms of influenza. These symptoms last less than a week and are noticeable within two days of exposure to the virus. Children are also affected by nausea and vomiting which are not common in adults.
The three types of influenza affecting people include the Type C, Type B, and Type A. The virus generally spreads through the medium of air via sneezes or coughs. The complicated cases of patients affected by influenza include sinus infections, viral pneumonia, deterioration of health problems such as asthma, and secondary bacterial pneumonia.
The market is being driven on the basis of rapid increase in the number of influenza affected populace, innovation in R&D activities, and the increasing public awareness. Further, the growth in healthcare expenditure coupled with the rising expenditure on healthcare, and increasing funds and investments from governments are further aiding the growth of the market. The antigenic shift of the influenza virus and the reported side-effects of drugs are the major restraints faced by the market.
Europe holds the second highest market share in the global market owing to being a seasoned market, developed healthcare market, and supportive governmental policies. The Europe region is geographically segmented into U.K, Germany, Spain, France, and Italy. UK leads the market in the region, followed by Germany and Italy.
We are pleased to offer you this exciting, new, and entirely free professional resource. Visit our Free Biotechnology & Pharmaceuticals resource center today to browse our selection of 600+ complimentary Biotechnology & Pharmaceuticals magazines, white papers, webinars, podcasts, and more. Get popular titles including:
